{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:43:44Z","timestamp":1780652624415,"version":"3.54.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.ejca.2014.01.009","type":"journal-article","created":{"date-parts":[[2014,2,2]],"date-time":"2014-02-02T20:31:04Z","timestamp":1391373064000},"page":"1247-1258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Targeted therapies in gastroesophageal cancer"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct00450203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01107639","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01170663","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01234324","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01248403","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01472029","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01585987","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01630083","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01662869","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01697072","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01774786","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stefan","family":"Kasper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2014.01.009_b0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial","volume":"28","author":"Ajani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2014.01.009_b0010","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0015","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1535-7163.MCT-08-0374","article-title":"HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells","volume":"7","author":"Bachleitner-Hofmann","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2014.01.009_b0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2014.01.009_b0025","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10637-010-9438-y","article-title":"Phase II study of sunitinib as second-line treatment for advanced gastric cancer","volume":"29","author":"Bang","year":"2011","journal-title":"Invest New Drugs"},{"issue":"Suppl. 34; abstr. 11","key":"10.1016\/j.ejca.2014.01.009_b0030","article-title":"A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study","volume":"30","author":"Bang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0040","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2014.01.009_b0045","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0050","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0055","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14728222.2012.680957","article-title":"Targeting the HGF\/Met signaling pathway in cancer therapy","volume":"16","author":"Cecchi","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ejca.2014.01.009_b0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12094-007-0041-4","article-title":"Molecular biology of gastric cancer","volume":"9","author":"Cervantes","year":"2007","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0070","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3748\/wjg.v19.i13.2073","article-title":"Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer","volume":"19","author":"Chen","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2014.01.009_b0075","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2014.01.009_b0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2014.01.009_b0095","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0100","first-page":"258","article-title":"Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1839) in pretreated patients with metastatic gastric cancer","volume":"22","author":"Doi","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2014.01.009_b0470","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","article-title":"Multicenter phase II study of everolimus inpatients with previously treated metastatic gastric cancer","volume":"28","author":"Doi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2014.01.009_b0105","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2014.01.009_b0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0115","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1200\/JCO.2006.07.1316","article-title":"Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127","volume":"24","author":"Dragovich","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2014.01.009_b0120","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2014.01.009_b0125","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-1970","article-title":"A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response","volume":"13","author":"Ferry","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.01.009_b0130","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","author":"Fuchs","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2014.01.009_b0135","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2014.01.009_b0140","first-page":"57","article-title":"HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value \u2013 conclusions from 924 cases of two independent series","volume":"32","author":"Grabsch","year":"2010","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.bjc.6604861","article-title":"Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer","volume":"100","author":"Han","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2014.01.009_b0155","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"Suppl.; abstr. LBA 4001","key":"10.1016\/j.ejca.2014.01.009_b0160","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013\/LOGiC Trial","volume":"31","author":"Hecht","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0170","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.humpath.2007.02.005","article-title":"Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction","volume":"38","author":"Kim","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2014.01.009_b0175","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s10637-009-9363-0","article-title":"A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and\/or recurrent advanced gastric cancer","volume":"29","author":"Kim","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2014.01.009_b0180","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0185","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","article-title":"EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number","volume":"52","author":"Kim","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2014.01.009_b0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bjc.2012.237","article-title":"MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome","volume":"107","author":"Lee","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2014.01.009_b0195","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjc.6605521","article-title":"Cetuximab plus oxaliplatin\/leucovorin\/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"102","author":"Lordick","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2014.01.009_b0200","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0205","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10637-013-0020-2","article-title":"Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study","volume":"31","author":"Martin-Richard","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2014.01.009_b0210","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/annonc\/mdq591","article-title":"Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study","volume":"22","author":"Moehler","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0215","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2011.04.006","article-title":"An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer","volume":"47","author":"Moehler","year":"2011","journal-title":"Eur J Cancer"},{"issue":"Suppl.; abstr. 4086","key":"10.1016\/j.ejca.2014.01.009_b0220","article-title":"FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: a randomized placebo-controlled multicentric AIO phase II trial","volume":"31","author":"Moehler","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl.; abstr. TPS4151","key":"10.1016\/j.ejca.2014.01.009_b0225","volume":"31","author":"Moehler","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0230","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0240","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2014.01.009_b0245","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J","article-title":"The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas","volume":"85","author":"Nakajima","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2014.01.009_b0250","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2014.01.009_b0255","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study","volume":"31","author":"Ohtsu","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0260","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2010.29.2847","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II\/III REAL-3 trial","volume":"28","author":"Okines","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0265","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrclinonc.2011.45","article-title":"Targeting the human EGFR family in esophagogastric cancer","volume":"8","author":"Okines","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0270","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1038\/sj.onc.1207726","article-title":"International variation","volume":"23","author":"Parkin","year":"2004","journal-title":"Oncogene."},{"key":"10.1016\/j.ejca.2014.01.009_b0275","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0280","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","article-title":"MET: a promising anticancer therapeutic target","volume":"9","author":"Peters","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0285","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/annonc\/mdl459","article-title":"Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)","volume":"18","author":"Pinto","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0290","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.bjc.6605319","article-title":"Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)","volume":"101","author":"Pinto","year":"2009","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2014.01.009_b0475","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: aphase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.01.009_b0300","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/annonc\/mdq247","article-title":"Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study","volume":"21","author":"Rao","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0305","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2014.01.009_b0310","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.01.009_b0315","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15_Suppl. 4080","key":"10.1016\/j.ejca.2014.01.009_b0320","article-title":"Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas","volume":"31","author":"Schuler","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0325","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0330","doi-asserted-by":"crossref","first-page":"e54014","DOI":"10.1371\/journal.pone.0054014","article-title":"Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET\/VEGFR2 inhibitor, in patients with metastatic gastric cancer","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2014.01.009_b0335","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ejca.2014.01.009_b0340","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2014.01.009_b0345","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection","volume":"30","author":"Smalley","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0350","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2014.01.009_b0355","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1399-0039.2006.00701.x","article-title":"PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies","volume":"69","author":"Sun","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ejca.2014.01.009_b0365","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1200\/JCO.2009.27.7988","article-title":"Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203","volume":"28","author":"Sun","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0370","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0375","first-page":"A5","article-title":"Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer","volume":"85","author":"Tew","year":"2005","journal-title":"Proc Gastrointest Am Soc Clin Oncol Symp"},{"key":"10.1016\/j.ejca.2014.01.009_b0380","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2014.01.009_b0385","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000277635","article-title":"Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I\/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"33","author":"Trarbach","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2014.01.009_b0390","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s10637-012-9848-0","article-title":"Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas","volume":"31","author":"Trarbach","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2014.01.009_b0395","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0400","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0405","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0410","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2014.01.009_b0415","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0420","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0430","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0435","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0440","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/bjc.2011.280","article-title":"Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction","volume":"105","author":"Wainberg","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2014.01.009_b0480","doi-asserted-by":"crossref","unstructured":"Wilke H, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, et al. RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol 2014;32(Suppl. 3; abstr. LBA7).","DOI":"10.1200\/jco.2014.32.3_suppl.lba7"},{"key":"10.1016\/j.ejca.2014.01.009_b0445","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0450","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0455","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2014.01.009_b0460","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2014.01.009_b0465","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T03:35:59Z","timestamp":1565148959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0959804914000434"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.01.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapies in gastroesophageal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}